title: Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
abstract: The introduction of immunotherapy with checkpoint receptor blockade has changed the treatment of advanced cancers, at times inducing prolonged remission. Nevertheless, the success rate of the approach is variable across patients and different tumor types, and treatment is often accompanied by severe immune-related side effects, suggesting the importance of co-inhibitory pathway for both prevention of autoimmunity and failure of tumor rejection. A better understanding of how to uncouple anti-tumor activity from loss of self-tolerance is necessary to increase the therapeutic efficacy of checkpoint immunotherapy. In this review, we describe basic concepts of T-cell exhaustion that occur in cancer, highlighting the role of co-inhibitory receptors in contributing to this process while preventing immunopathology. By providing an overview of the current therapeutic success and immune-related burden of secondary effects of checkpoint immunotherapy, we illustrate the "double-edged sword" related to interference with immune-regulatory pathways. Finally, since achieving tumor rejection while preserving self-tolerance is particularly important for the central nervous system, we analyze the case for checkpoint immunotherapy in glioblastoma, the most common adult brain tumor.
authors.affiliation: Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.
authors.forename: Liliana E
authors.initials: LE
authors.lastname: Lucca
authors.affiliation: Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Hafler
mesh_terms: D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000276:immunology*; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000379:methods*; D017634:Self Tolerance; D013601:T-Lymphocytes / Q000276:immunology*; D019139:Tumor Escape
chemical_list: D000911:Antibodies, Monoclonal; D061025:Costimulatory and Inhibitory T-Cell Receptors
keywords: T-cell exhaustion; coinhibitory receptor; glioblastoma; tolerance